Clinical trial data demonstrate that Cavhanza can be taken with or without food, offering patients greater administration convenience.
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Asciminib, a first-in-class BCR-ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line ...
A KAIST research team has identified the real reason why anticancer drugs kill cancer cells—targeted anticancer therapies do not simply block cancer proteins but rather shut down the "protein ...
The ASCO Annual Meeting is the world’s most prominent scientific gathering in the clinical oncology community, showcasing cutting-edge research in clinical oncology and advanced cancer therapies. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results